title: Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization.
abstract: OBJECTIVE
  To compare the effects of one intravitreal bevacizumab (IVB) injection with three monthly injections for myopic choroidal neovascularization.
  
  
  METHODS
  Group A included 13 patients treated with one IVB injection; group B included 19 patients treated with three monthly 1.25-mg IVB injections. All patients were followed monthly for 12 months with additional injections performed as needed. The best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment.
  
  
  RESULTS
  The mean logMAR BCVA improved from 0.59 to 0.49 at 12 months in group A (p = 0.21) and from 0.65 to 0.29 in group B (p < 0.001); the improved logMAR BCVA differed significantly between the groups (p < 0.05). The mean CFT decreased from 231 μm at baseline to 150 μm at 12 months in group A (p < 0.05) and from 279 to 156 μm in group B (p < 0.001). During the follow-up, 6 of 13 eyes in group A and 5 of 19 eyes in group B received additional injections.
  
  
  CONCLUSIONS
  Treatment starting with three monthly IVB injections may achieve better functional outcomes with fewer retreatments compared with treatment starting with one IVB injection.
authors: Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan. yuichi @ belle.shiga-med.ac.jp
authors: Yuichi
authors: Y
authors: Niwa
authors: Osamu
authors: O
authors: Sawada
authors: Taichiro
authors: T
authors: Miyake
authors: Masasi
authors: M
authors: Kakinoki
authors: Tomoko
authors: T
authors: Sawada
authors: Hajime
authors: H
authors: Kawamura
authors: Masahito
authors: M
authors: Ohji
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab